GlaxoSmithKline and Merix settle extended dispute over advertising practices

CHICAGO According to court documents filed last month, Merix Pharmaceutical and GlaxoSmithKline have settled a three-year dispute over advertising and competition practices for an undisclosed amount. “In exchange for certain consideration, the settlement agreement calls for Merix to dismiss with prejudice its claims against GSK, with each side to bear its own costs, expenses and attorneys’ fees,” the court documents, filed Sept. 2, read.

Merix had filed suit in March 2005 charging that certain advertising claims made by GlaxoSmithKline in support of its cold sore remedies Abreva and Valtrex may be false and misleading, using unreliable test data to promulgate advertising claims in an intentional effort to deceive doctors and the public.